Volver

Sanofi ADR

Ticker: SNY ISIN: US80105N1054
Añadir al portafolio Análisis de cartera en 2min
Stock Large-cap
Capitalización
116,71 MM $
P/E
15,69
Forward P/E
9,78
Profit margin
19,84%
Revenue growth QoQ
-7,00%
Div. yield
0,00%
Beta
0,40
45,69 $ -0,35%
Precio a fecha de 2026-08-24 · NASDAQ

Rendimiento por período

Rendimientos acumulados
1 Month +3,84%
6 Months +1,93%
1 Year -3,80%
5 Years +1,81% p.a.+9,37%
10 Years +5,89% p.a.+77,18%
Since inception +5,62% p.a.+274,81%
Rendimientos por año
YTD -0,49%
2025 +4,93%
2024 +1,09%
2023 +6,71%
2022 +0,47%
2021 +7,00%

Key stats

Market cap
116,71 MM
P/E
15,69
Dividend yield
0,00%
Beta
0,40
52-week range
44.62 - 57.57
50-day MA
49,52
200-day MA
49,86
Section 1

Business overview

Company profile data from fundamentals.

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sector Healthcare
Industry Drug Manufacturers - General
Country France
Exchange NASDAQ
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 8,84%
ROA 4,61%
Profit margin 19,84%
Operating margin 28,73%
PEG ratio 0,73
Revenue/share TTM 18,66
Revenue TTM 45,93 MM
EBITDA 12,33 MM
Gross profit TTM 33,07 MM
Beta 0,40

Valuation

Trailing P/E 15,69
Forward P/E 9,78
P/B 1,36
P/S 2,54
EV/EBITDA 8,35
EV/Revenue 2,30
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 4,56
Quarterly earnings growth 2,40%
Revenue TTM 45,93 MM
Reported quarters 65
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 0,00%
Forward annual div. yield 4,56%
Dividend per share 0,0000
Payout ratio 51,46%
Ex-dividend date 2025-05-09
Split factor 5:1
Last split date 2013-09-30
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 58,68 $
Analyst rating 4.1818

Ownership & short interest

Shares outstanding 2,42 MM
Shares float 1,10 MM
Institutional ownership 9,89%
Insider ownership 0,10%
Short ratio 2,76
Short % of float 0,35%

Details

Instrument metadata and source update timestamps.

Symbol SNY
Name Sanofi ADR
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US80105N1054
Country USA
Code + exchange SNY.NASDAQ
Last price date 2026-01-06
Fundamentals updated 2026-01-07

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.